Medindia

X

ANA598 Demonstrates 73% cEVR in Combination With Interferon and Ribavirin

Thursday, February 25, 2010 Medical PDA News J E 4
Advertisement
No Viral Rebound Observed During 12 Weeks of ANA598 Dosing

Proportion of Patients with Undetectable Levels of Virus (<15 IU/mL) by Week

Week 4

(RVR)

Week 6

Week 8

Week 10

Week 12*

(cEVR)

ANA598 + SOC

56%

65%

69%

73%

73%

Placebo+ SOC

20%

27%

47%

54%

71%

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Anadys Pharmaceuticals Reports Fourth Quarter and ...
S
Transgenomic Reports Fourth Quarter Financial Resu...